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“Good stereotactic surgery for movement disorders can be performed
with or without the microelectrode, and poor surgical results can
occur both with and without the microelectrode.” – Dr. Roy Bakay1
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Figure 1
Early methods of localizing deep brain structures. A. Anteroposterior and B. lateral views
of a pneumoencephalogram obtained by filling the ventricles with air; and C. Anteroposterior and D. lateral views of a ventriculogram obtained by injecting the ventricles with
contrast medium.
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A BRIEF HISTORY OF DBS
AND NEUROIMAGING
Stereotactic neurosurgery is founded
on the ability to accurately localize
and safely access targets within the
brain in a minimally-invasive manner.
The stereotactic method was first
described in 1908 by Sir Victor Horsley
and Robert Clarke at University College
London, where they developed an
apparatus for animal experimentation
that allowed them to establish a threedimensional Cartesian coordinate system
for targeting. At that time, however,
x-rays were the only available form of
imaging the human body and as such,
localizing intracranial targets relied
on a combination of knowledge from
anatomical atlases and the visualization
of a few intracranial landmarks such
as the pineal gland or the foramen of
Monroe. These landmarks could be
visualized by filling the ventricles with air
(pneumoencephalogram) or a contrast
medium (ventriculogram) [Figure 1]. In
1947, Ernst Spiegel and Henry Wycis
created the first human stereotactic
frame that allowed for lesioning of
deep brain nuclei for the treatment of
psychiatric disease. 2
With imaging limited to x-rays alone,
a need arose for another means of
confirming the appropriate location
where a lesion would be made or
an electrode would be implanted.
Nicholas Wetzel and Ray S. Snider
have been accredited with performing
the first microelectrode recording
(MER) in humans in 1958 during a
pallidotomy. 3 Over time, particularly
with the popularization of thalamotomy
for the treatment of Parkinson’s disease
and with a growing appreciation of
characteristic recordings of specific
nuclei, MER became commonplace in
stereotactic neurosurgery.

Over the following decades, deep
brain stimulation (DBS) gained favor
over ablation due to a lower side effect
profile and to the ability to reverse the
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effects of the former. As with early deep brain lesioning, deep electrical stimulation of brain structures was originally introduced as a therapeutic option to treat
behavioral disorders or chronic pain. 2 Natalia Petrovna Bekthereva was the first to
implant electrodes into subcortical structures for chronic stimulation for hyperkinetic disorders, but the idea to use chronic stimulation as a therapeutic method
did not emerge until Alim-Louis Benabid’s report in 1987 on stimulation of the Vim
nucleus for treating a patient with tremor. 2
It is also in this decade that the field of neuroimaging was completely changed by
the introduction of magnetic resonance imaging (MRI). Improvements in imaging
began a decade earlier, however, when the first clinical computed tomography
(CT) scan was performed in 1971 [Figure 2].4 While better than x-rays, CT scans
were still limited in their ability to represent soft tissue. This limitation would be
addressed by MRI, which also emerged in the 1970s; and the first MR images of a
human brain were generated in 1978 [Figure 3a].5 Nevertheless, images generated
on clinical MR scanners were still not capable of accurately representing targets
such as the subthalamic nucleus (STN) or the globus pallidus pars interna (GPi).
As such, DBS targeting continued to rely on previously established locations from
accepted atlases, such as that of Schaltenbrand and Wahren. In order to account
for anatomical variation between patients, MERs and awake testing were necessary
to ensure proper positioning of DBS electrodes.
With sufficient safety and efficacy data, the Food and Drug Administration (FDA)
approved DBS as a treatment for essential tremor in 1997 and for Parkinson’s
disease in 2002.6 Now, more than 135,000 patients worldwide have received DBS
therapy.7 While the majority of centers continue to perform the surgery awake and
with MER, there has been a trend towards performing the surgery under general
anesthesia and without MER. Improvements in technology and a deeper understanding of MRI physics has allowed for clearer and more accurate representations
of intracranial anatomy [Figure 3b-d]. We are now able to consistently visualize the
borders of deep brain nuclei on MR images acquired on clinical scanners, which
in turn facilitates surgical planning and allows for an image-guided, image-verified
approach to DBS implantation [Figure 4]. Overall, it is the advances in both surgical
technologies and neuroimaging techniques that have allowed for the maturation of
stereotactic neurosurgery over the past several years. Here, we will outline both the
“awake” and “asleep” versions of the surgical procedure; and provide an overview
of the pros and cons of each approach.

DBS VERIFIED BY MICROELECTRODE RECORDINGS
AND MACROSTIMULATION
The most common method of implanting DBS electrodes in the United States involves
microelectrode recordings (MERs) and macrostimulation in an awake patient. As
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mentioned above, this technique allows
the surgeon to confirm the target for
electrode placement with neurophysiologic recordings and immediate clinical
response.
At our institution, the trajectory to the
desired target is first planned on a T2
weighted or proton density (PD) MRI as
well as on volumetric (1cm3 voxel) T1
weighted gadolinium-enhanced MRI. In
order to optimize MERs and the reliability
of intraoperative testing, the patient’s

Figure 2
The first clinical computed tomography (CT) scan performed in 1971 at
Atkinson Morley's Hospital, in London,
England.
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Figure 3
The evolution of magnetic resonance imaging (MRI) A. The first clinical MRI was performed in 1978 in England. Since then, imaging has
improved significantly with increasing magnet strength from B. 3T imaging first performed in 1984, C. 7T imaging first performed in 1999,
and D. 9.4T imaging first performed in 2007.
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medications are held to ensure that they

Figure 4

trajectory in real space. In the operating

Magnetic resonance images (MRI) can now be optimized to clearly visualize deep brain
structures for targeting in deep brain stimulation (DBS). A. A T2 sequence MRI is used to
visualize the subthalamic nucleus (STN) B. highlighted in red; and C. A proton density (PD)
sequence MRI is used to visualize the globus pallidus (GP) D. highlighted in red

are in the OFF-state during the time of
surgery. The first stage of the procedure
starts with placement of a stereotactic
(Leksell) frame under local anesthesia.
After a reference CT is acquired with the
frame on the patient, this image is merged
with the MRI containing the stereotactic
plan. This step allows for the calculation of the stereotactic Leksell frame
coordinates, which defines the planned
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room, the patient is positioned in a
semirecumbent position with the head
fixed to the operating room table. Under
monitored anesthetic care, incisions are
made in the scalp and 14mm burr holes
are drilled in the skull. Once the dura
and pia have been sharply opened, the
microelectrode drive is assembled on
the Leksell frame. It is at this time that
the patient is awakened and MERs are

performed to confirm the desired target
based on characteristic neuronal firing
patterns [Figure 5]. If MERs do not confirm
appropriate placement, a new tract is
made to help optimize electrode position. The location of this tract is typically
offset by 2mm from the original tract and
depends on the MERs and the neurosurgeon’s knowledge of the surrounding
anatomy. Only after MERs have been
optimized and the most suitable location has been mapped is the electrode
implanted. Across multiple centers, the
average number of MER tracts has been
reported to be 2.3 for each implanted
electrode. 8,9 After the DBS electrode
has been placed into the desired deep
brain target, it is subjected to intraoperative test stimulation in order to confirm
therapeutic efficacy and ensure that there
are no associated side effects. If a second
electrode is to be implanted, this process
is repeated. With both electrodes in their
final location, the ends of the wires are
capped and tunneled under the skin to a
point behind the patient’s ear. In a review
of the literature, the mean operating
room time for a unilateral DBS implantation was reported to be 223.83 minutes;
and 279.79 minutes for simultaneous
bilateral implantation.10
The second stage of the procedure
consists of connecting the intracranial
electrode wires to an implantable pulse
generator. This portion of the procedure is always performed under general
anesthesia, and may be performed either
on the same day as the first stage, or
in a delayed fashion as an outpatient
procedure.

DBS VERIFIED BY
INTRAOPERATIVE IMAGING
Over the past several years, a growing
number of centers have started to offer
DBS surgery under general anesthesia –
or “asleep” DBS. The main premise of this
approach is that MRI technology is now
capable of clearly identifying the anatomy
of the deep brain target; and that intraoperative imaging can be used to verify
the location of the DBS lead in this target.
As such, both MRI11–13 and CT14–17 have
been used to accomplish the necessary
task of image verification in “asleep”
DBS. Although intraoperative MRI allows
for direct visualization of the electrode
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Figure 5
Dr. Ashwini D. Sharan inserts the DBS electrode into its final position after verifying its
optimal position with microelectrode recordings. Macrostimulation will then be used to
test for therapeutic effect and rule out side effects from stimulation.

Figure 6
Dr. Chengyuan Wu performs an “asleep” DBS surgery in which the final electrode position
is confirmed with intraoperative imaging.

without the need for image fusion, the
use of intraoperative CT has been found
to be safe and accurate as well.18

At our institution, the trajectory to the
desired target is once again planned

on a T2 weighted or proton density
(PD) MRI as well as on volumetric
(1cm3 voxel) T1 weighted gadoliniumenhanced MRI. The first stage of
the procedure similarly starts with

placement of a stereotactic (Leksell)
frame under local anesthesia. After a
reference CT is acquired with the frame
on the patient, this image is merged
with the MRI containing the stereotactic
plan. Again, this step allows for the
calculation of the stereotactic Leksell
frame coordinates or robotic (Renishaw
Neuromate) arm position, which defines
the planned trajectory in real space.
In the operating room, the patient is
placed under general anesthesia and
positioned in a supine position with
the head fixed to the operating room
table or to the stereotactic robot. The
intraoperative CT (Medtronic O-Arm)
is also brought into position around
the surgical field. Incisions are made in
the scalp and 2mm twist drill holes are
drilled into the skull [Figure 6]. After the
dura has been opened sharply and with
cauterization, a radiofrequency probe
is passed down the planned trajectory in order to measure impedances,
which helps to confirm a target in gray
matter. The electrode is implanted at
this location and secured in place to the
skull. The same process is repeated for
the second electrode before an intraoperative CT scan is acquired. Before
closing the incisions, this intraoperative
image is merged back to the original
plans and the accuracy of electrode
placement is critically assessed. Only
if the electrode is within the intended
deep brain nucleus and within 2mm of
its intended trajectory is it considered
to be in an appropriate position. This
verification step is critical and systematic analysis of targeting errors permits
development of strategies to improve
surgical accuracy and precision during
subsequent procedures.19
With both electrodes in their final location, the wires are tunneled under the
skin to a point behind the patient’s ear.
The second stage of the procedure
consists of connecting the intracranial
electrode wires to an implantable pulse
generator, which is usually performed
on the same day.

EQUIVALENCE BETWEEN
TECHNIQUES
Clinical Outcomes
In a large multicenter study performed
in the UK and published in 2010, 366
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patients with Parkinson’s disease across 13
centers were randomized to surgery and
best medical therapy or to best medical
therapy alone. They found that there was
a significant improvement in quality of life
ratings, specifically with mobility, activities of daily living, and bodily discomfort
in patients that received surgical intervention in addition to medical therapy. 20
Specifically, patients who underwent
MER-guided DBS for Parkinson’s disease
have demonstrated a 26-33% improvement in UPDRS-III motor scores after 6
months.12,21,22 Furthermore, these effects
are long lasting with substantial benefits
for symptoms such as tremor, rigidity,
and motor complications; whereas other
symptoms of akinesia, axial signs, and
cognition often continue to deteriorate
as part of the natural progression of the
disease. 23–25
The outcomes in patients undergoing “asleep” DBS has certainly been
comparable, with patients experiencing
a 40-66% improvement in UPDRS-III
motor scores after 6 months. 15,26,27
Similarly, 41 patients who underwent
“asleep” STN DBS continued to demonstrate significant reduction of motor
fluctuations, dyskinesias, and demands
in dopaminergic medications at 5 years
after implantation; however axial symptoms and bradykinesia continued to
worsen as part of disease progression. 28
A direct comparison between the two
approaches was performed by Saleh et
al, who performed a retrospective review
in which they compared 14 patients who
underwent DBS placement under general
anesthesia to 23 patients who underwent
DBS placement while awake with MER.
After 6 months of therapy, both groups
showed statistically similar reductions in
levodopa equivalent dosages.29

Associated Costs
A 2011 review of literature to date
suggested that MER doubled, or even
tripled, the cost of DBS implantation
compared to surgery performed without
MER.10 Given its retrospective nature,
however, this study compared costs across
multiple centers and was limited to the
reported costs associated with the surgery
itself. More recently, a single center study
from Oregon Health and Science University reported no significant difference in
cost between “awake” ($40,052 ± $6,604)
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and “asleep” ($38,850 ± $4,830) DBS when
they compared 53 “awake” to 158 “asleep”
procedures performed over a 5 year span
at their institution.30 While they reported
a lower variation in procedural costs, it
is important to note that this study also
include all costs incurred both 30 days
before and after surgery.

BENEFITS OF “AWAKE” DBS
Use of MER in an awake patient for DBS
implantation certainly has a tried and true
track record. It can be performed reliably
even when the borders of intended deep
brain target cannot be directly visualized.
While clinical MR scanners are generally
capable of imaging many of these targets,
expertise in both MR physics and the
surgical technique of DBS are necessary
to establish protocols for the necessary
image sequences. Furthermore, not all
clinical targets are yet visible on clinical MR
scanners—the borders of the ventral intermediate nucleus (Vim) of the thalamus still
cannot be clearly distinguished. In such
scenarios, the use of MERs increases the
accuracy of DBS electrode placement.31,32
Even when the borders of the target,
such as the subthalamic nucleus (STN) or
globus pallidus pars interna (GPi), can be
clearly seen, some have pointed out that
the subregion of the sensorimotor region
of this nucleus cannot be visualized and
discerned from the cognitive and limbic
regions of the nucleus.33
Another major benefit of “awake” DBS is
the ability to perform intraoperative stimulation testing. The ability to immediately
confirm the therapeutic efficacy of stimulation as well as ensure the absence of no
side effects can certainly be reassuring not
only for the neurosurgeon, but also for the
patient undergoing the procedure. Finally,
by having the procedure performed awake,
the risks of undergoing general anesthesia
are completely eliminated. It is for these
reasons that many centers continue to
perform DBS in this manner.

BENEFITS OF “ASLEEP” DBS
Increased Patient Comfort
While intraoperative testing provides
immediate feedback, the time requirement of both MERs and stimulation testing
for which the patient must be awake can
be challenging for patients, who can
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fatigue, lose concentration, and in doing
so, potentially reduce the reliability of
this intraoperative testing.34 In contrast,
“asleep” DBS is associated with increased
patient comfort, reduced anxiety, less back
pain, and fewer anesthetic concerns about
respiratory difficulties.19,35,36 In addition,
since no intraoperative neurophysiologic
or clinical testing is being performed
there is no need to force the patient to
an OFF-state; and the lack of complete
levodopa reduces tremor severity, painful
“off” dystonia or rigidity, “off” anxiety, and
confusion for the patient.19,27,35,36 The
result of all of these factors is more rapid
mobilization after surgery and a overall
shorter recovery period. Lastly, although
more difficult to interpret than in awake
patients, MERs can even be performed
during “asleep” surgery and has been
reported by a few institutions.34–36

Shorter Operating Time
In eliminating the need for intraoperative
recording and testing, “asleep” DBS also
tends to offer shorter surgical times. As
greater comfort and experience is gained
with this technique, operative times have
improved.29 In a retrospective analysis,
surgical time was reduced by an average
of 175 minutes if a single electrode was
implanted without MER.10 Such a reduction of the duration which a patient must
remain on an operating room table has
been suggested to decrease the risk of
venous thrombosis and pulmonary embolism.34 In addition, shorter surgical times
may be related to patient comfort factors
mentioned in the previous section.

Increased Accuracy
If MR imaging is not, or cannot be, optimized for a particular deep brain target,
the surgeon must rely on ventricular
landmarks, prior knowledge based on
established atlases, and MER to identify
the appropriate location for electrode
implantation. Such indirect imaging
methods have led to the initial track being
used in 70% of cases and an average of
2.3 tracts per implanted electrode.8,9,37
In comparison, a single brain penetration is sufficient in 87-95% of patients
undergoing MRI-guided and MRI-verified
DBS; with only one additional track was
required in the remainder.37,38
During DBS surgery under general anesthesia, it has been theorized that the
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positive-pressure ventilation increases
intracranial pressure, which to some
extent reduces brain shift. In addition
with meticulous entry planning on a
gyrus and shorter surgical times are felt to
reduce egress of cerebrospinal fluid and
pneumocephalus, which further reduces
stereotactic inaccuracy from brain shift.39
In our practice, we feel that we further
reduce these deleterious factors by
keeping the patient supine and by drilling
only a 2mm twist drill hole.

image-guided DBS without MER, Zrinzo
et al reported a total incidence of ICH
of was 0.9%, with asymptomatic in 0.5%
of patients, symptomatic hemorrhage
in 0.5%, and hemorrhage resulting in
permanent deficit in 0.0% of patients.50
Overall this equates to a four to five fold
increase in hemorrhage risk in awake
surgery performed with MER.

In published series of “asleep” DBS to
date, the mean deviation of the implanted
electrode when compared to the intended
trajectory is only 1.2mm.14,15,40 While
advocates of MER may argue that this
low deviation supports precision and not
necessarily accuracy, current experience
has also shown that the site of best MER
activity does not necessarily correlate
with best clinical response during intraoperative testing or long-term outcome.41,42
Furthermore, in the setting of improved
perioperative imaging, there exists no
evidence that MER help prevent suboptimal electrode placement.10,43–46 In fact,
cases of mistaking the recordings of the
red nucleus for STN highlight the false
sense of security that MER can provide.47

Despite the significant differences
between these two techniques outlined
above, their clinical outcomes and
procedural costs to date have been
largely the same. While the benefits of
neurophysiologic and clinical confirmation advocate for “awake” DBS, the
advantages of greater patient comfort,
decreased operating time, increased
accuracy, and reduced hemorrhagic
complications support “asleep” DBS. As
such, it is important to discuss these
factors with patients considering DBS
surgery. Each approach has its own
advantages and disadvantages that must
be weighed with patient-specific factors,
concerns, and preferences.

Reduced Risk of Intracranial
Hemorrhage
One of the main arguments for DBS to be
performed without MER is that there is an
increased risk of intracranial hemorrhage
with increased brain penetrations.31,48
In a 2011 meta-analysis of 109 studies
comprising 6,237 patients and 9,890
trajectories to deep nuclei, the estimated
per-trajectory intracerebral hemorrhage
(ICH) rate was 1.57% with an estimated
mortality rate per trajectory was of 0.14%.
The use of MER and multiple trajectories
to deep nuclei were both positive predictors of increased ICH risk.49,50 As illustrated
above, the image-guided image-verified
electrode implantation is associated
with fewer brain penetrations, which
contributes to reducing the associated
risk of ICH. When evaluated separately,
the overall incidence of ICH in functional
neurosurgery has been reported to be
5.0%, with asymptomatic hemorrhage
in 1.9% of patients, symptomatic hemorrhage in 2.1% and hemorrhage resulting
in permanent deficit or death in 1.1%. In
comparison, in 214 patients undergoing

CONCLUSION
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